

Keytruda® (pembrolizumab) – Expanded indication

- On October 16, 2023, Merck announced the FDA approval of Keytruda (pembrolizumab), for the treatment of patients with resectable (tumors ≥ 4 cm or node positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.
 - With this approval, Keytruda has six indications in NSCLC, across both metastatic and earlier stages of NSCLC.
- Refer to the Keytruda drug label for a complete list of Keytruda's other indications and uses.
- The approval of Keytruda for the expanded indication was based on KEYNOTE-671, a randomized, double-blind, placebo-controlled study in 797 patients with previously untreated and resectable Stage II, IIIA, or IIIB (N2) NSCLC. Patients were randomized to: (1) neoadjuvant Keytruda in combination with chemotherapy followed by single agent Keytruda, or (2) neoadjuvant chemotherapy followed by placebo. The major efficacy measures were overall survival (OS) and event-free survival (EFS).
 - Median OS was not reached in the Keytruda arm vs. 52.4 months in the placebo arm (hazard ratio [HR] 0.72, 95% CI: 0.56, 0.93; p = 0.0103).
 - Median EFS was not reached in the Keytruda arm vs. 17.0 months in the placebo arm (HR 0.58, 95% CI: 0.46, 0.72; p < 0.0001).
- The recommended dose of Keytruda for adult patients with NSCLC is 200 mg every 3 weeks or 400 mg every 6 weeks via intravenous infusion.
 - Neoadjuvant treatment should be given in combination with chemotherapy for 12 weeks
 or until disease progression that precludes definitive surgery or unacceptable toxicity,
 followed by adjuvant treatment with Keytruda as a single agent after surgery for 39 weeks
 or until disease recurrence or unacceptable toxicity.
 - Refer to the Keytruda drug label for dosing for all its other uses.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.